Genprex, Inc. (NASDAQ:GNPX)

US · Delayed Price · Currency is USD

3.43-0.11 (-3.11%)

Market Cap	1.73M-98.8%
Revenue (ttm)	0
Net Income	-16.50M+4.6%
EPS	-158.78+93.1%
Shares Out	504.94K
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	25,789
Open	3.54
Previous Close	3.54
Day's Range	3.37 - 3.56
52-Week Range	3.36 - 1210.00
Beta	n/a
Analysts	Buy
Price Target	n/a
Earnings Date	Dec 2, 2026

-3.67% (1D)

No price history available.

Full Chart

Alerts Compare

About GNPX

Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission revolves around developing innovative therapies for patients battling cancer and diabetes. Leading their product pipeline is REQORSA (GPX-001), a flagship gene therapy candidate specifically designed to target both non-small cell lung cancer and small cell lung cancer. In addition, Genprex is progressing GPX-002, another gene therapy at the preclinical stage, intended for the management of diabetes. The company was established in 2009 and operates from its corporate headquarters located in Austin, Texas.

Address

3300 Bee Cave Road, Austin, TX, 78746, US

Market Cap

2 million

Employees

Industrial Classification

Biotechnology

1 Day

-3.11%

5 Days

-4.72%

1 Month

-18.14%

6 Months

-92.20%

1 Year

-98.75%

$GNPX stock is featured in our Congress Trading, and Insider Trades datasets.

→ All Stock Lists

Congress Trading

Recent trades of GNPX by members of U.S. Congress

Politician	Type	Traded
Tim MooreHouse / R	Purchase$1.00K – $15.00K	Feb 4, 2026
Tim MooreHouse / R	Purchase$1.00K – $15.00K	Dec 17, 2025
Tim MooreHouse / R	Purchase$1.00K – $15.00K	Nov 6, 2025
Tim MooreHouse / R	Purchase$15.00K – $50.00K	Oct 28, 2025

Whale Activity →

Recently reported changes in GNPX holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by GNPX's directors and management

No SEC Form 4 activity for GNPX in the last 5 quarters.

Source: SEC EDGAR (Form 4)

Corporate Lobbying

GNPX Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New GNPX patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to GNPX from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in GNPX

ETF	Est. Holding Size
VXFVanguard Extended Market ETF	$9.90K

Estimated from each fund’s disclosed top holdings × AUM

GNPX Insider Score

Our composite score: insider buying, sector, volume, tone & dilution

No Insider Score for GNPX yet — no open-market insider buys or sells in the last 90 days.

Bull Case vs Bear Case

AI-generated from GNPX’s recent data — informational, not investment advice

Generating analysis…

Recent Insider Activity

No Form 4 filings in the last 90 days.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.